Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pharmacokinetic Study on Echinocandins for Patients With Septic Shock Following Secondary Peritonitis
NCT02805049Phase 4Completed
- Sponsor
- CHU Nîmes
- Start
- Jan 2017
- Primary completion
- Jun 2018
- Modality
- Cyclic Peptides, Antimicrobial Peptides, Small Molecules
- Countries
- 2
01
Overview
A Phase 4 trial of caspofungin, micafungin in septic shock, peritonitis, sponsored by CHU Nîmes. Started Jan 2017; status: completed.
02
Drugs
caspofunginmicafungin
03
Conditions
septic shockperitonitis
Beyond the preview
Go deeper on NCT02805049.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02805049.